We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > servier

News List

Servier terminates CTI cancer pact following clinical failure fiercebiotech
February 28, 2019
Servier has terminated its Pixuvri collaboration agreement with CTI BioPharma. The action comes seven months after the B-cell non-Hodgkin lymphoma drug failed a key clinical trial....
CTI, Servier’s Pixuvri fails in post-marketing trial pharmatimes
July 16, 2018
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche's MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Servier opens Kendall Square site, plans Chinese office to access external innovation fiercebiotech
June 11, 2018
Servier has opened a site in Kendall Square and staffed it with people from Biogen and the University of Massachusetts to find R&D and licensing opportunities.
Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractor americanpharmaceuticalreview
March 13, 2017
Servier, together with Pfizer announced that the U.S. Food and Drug Administration (FDA) has granted Servier with an Investigational New Drug (IND) clearance to proceed in the U.S.

Previous page 1 2 3 Next page